Prise en charge du cancer du col de l’utérus métastatique et/ou en rechute

Abstract

The prognosis of metastatic or recurrent cervical cancer remains dismal. The poor chemosensitivity of this tumor- is an issue, especially in case of recurrence in irradiated fields. Still, chemotherapy has shown some efficacy, and mostly consists in platinum-based doublets. The addition of bevacizumab to chemotherapy has been recently validated. However, most of these patients present with complex clinical situations and the treatment strategy has to be discussed in multidisciplinary tumor boards.

Keywords: Cancer du col de l’utérus; Cervical cancer; Metastases; Métastases; Rechute; Recurrent disease; Traitement; Treatment.